Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) shares were down 5.6% on Friday after an insider sold shares in the company. The stock traded as low as $13.75 and last traded at $14.49. Approximately 2,035,512 shares were traded during mid-day trading, a decline of 1% from the average daily volume of 2,063,021 shares. The stock had previously closed at $15.35.
Specifically, CEO Christopher Richard Anzalone sold 81,500 shares of the firm’s stock in a transaction on Friday, November 9th. The stock was sold at an average price of $14.39, for a total value of $1,172,785.00. Following the completion of the sale, the chief executive officer now owns 1,727,755 shares of the company’s stock, valued at $24,862,394.45. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Kenneth Allen Myszkowski sold 45,000 shares of the firm’s stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $19.34, for a total value of $870,300.00. Following the completion of the sale, the chief financial officer now directly owns 335,815 shares of the company’s stock, valued at approximately $6,494,662.10. The disclosure for this sale can be found here. In the last three months, insiders sold 522,471 shares of company stock valued at $7,638,974. 4.60% of the stock is owned by corporate insiders.
ARWR has been the subject of a number of research analyst reports. BidaskClub cut Arrowhead Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 16th. Chardan Capital restated a “buy” rating and issued a $17.50 price target on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 13th. William Blair restated an “outperform” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, October 17th. B. Riley raised their price target on Arrowhead Pharmaceuticals from $12.00 to $18.00 and gave the company a “neutral” rating in a research report on Wednesday, August 8th. Finally, Cantor Fitzgerald set a $18.00 price target on Arrowhead Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, September 6th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $21.45.
The company has a current ratio of 8.69, a quick ratio of 8.69 and a debt-to-equity ratio of 0.02.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01. The business had revenue of $0.73 million during the quarter, compared to analysts’ expectations of $0.62 million. Arrowhead Pharmaceuticals had a negative return on equity of 59.39% and a negative net margin of 400.13%. Sell-side analysts forecast that Arrowhead Pharmaceuticals Inc will post -0.65 EPS for the current fiscal year.
A number of institutional investors have recently bought and sold shares of ARWR. RTW Investments LP increased its position in Arrowhead Pharmaceuticals by 184.6% during the 2nd quarter. RTW Investments LP now owns 8,299,542 shares of the biotechnology company’s stock worth $112,874,000 after purchasing an additional 5,382,981 shares in the last quarter. BlackRock Inc. increased its position in Arrowhead Pharmaceuticals by 108.1% during the 2nd quarter. BlackRock Inc. now owns 7,083,926 shares of the biotechnology company’s stock worth $96,342,000 after purchasing an additional 3,679,986 shares in the last quarter. FMR LLC purchased a new stake in Arrowhead Pharmaceuticals during the 3rd quarter worth about $37,922,000. Northern Trust Corp increased its position in Arrowhead Pharmaceuticals by 380.1% during the 2nd quarter. Northern Trust Corp now owns 1,063,499 shares of the biotechnology company’s stock worth $14,464,000 after purchasing an additional 841,982 shares in the last quarter. Finally, First Manhattan Co. increased its position in Arrowhead Pharmaceuticals by 11.6% during the 3rd quarter. First Manhattan Co. now owns 5,053,925 shares of the biotechnology company’s stock worth $96,883,000 after purchasing an additional 523,675 shares in the last quarter. Hedge funds and other institutional investors own 59.34% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/11/10/arrowhead-pharmaceuticals-arwr-trading-down-5-6-following-insider-selling.html.
Arrowhead Pharmaceuticals Company Profile (NASDAQ:ARWR)
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.
See Also: Bear Market
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.